This company listing is no longer active
Quia Pharma (QUIA) Stock Overview
Engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
QUIA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Quia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.0005 |
| 52 Week High | SEK 0.03 |
| 52 Week Low | SEK 0.0005 |
| Beta | 0.56 |
| 1 Month Change | -80.00% |
| 3 Month Change | -87.50% |
| 1 Year Change | -97.18% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| QUIA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -37.5% | 2.9% | 1.8% |
| 1Y | -97.2% | 30.5% | 14.1% |
Return vs Industry: QUIA underperformed the Swedish Biotechs industry which returned -4.9% over the past year.
Return vs Market: QUIA underperformed the Swedish Market which returned 4.1% over the past year.
Price Volatility
| QUIA volatility | |
|---|---|
| QUIA Average Weekly Movement | 32.7% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: QUIA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: QUIA's weekly volatility (33%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 2 | Richard Glimstedt | www.quiapeg.com |
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.
Quia Pharma AB (publ) Fundamentals Summary
| QUIA fundamental statistics | |
|---|---|
| Market cap | SEK 982.64k |
| Earnings (TTM) | -SEK 32.47m |
| Revenue (TTM) | SEK 460.00k |
Is QUIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QUIA income statement (TTM) | |
|---|---|
| Revenue | SEK 460.00k |
| Cost of Revenue | SEK 276.00k |
| Gross Profit | SEK 184.00k |
| Other Expenses | SEK 32.65m |
| Earnings | -SEK 32.47m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 40.00% |
| Net Profit Margin | -7,058.04% |
| Debt/Equity Ratio | 0% |
How did QUIA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/15 11:18 |
| End of Day Share Price | 2025/12/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quia Pharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.